These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8471323)

  • 1. Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer.
    Mulder NH; Mulder PO; Sleijfer DT; Willemse PH; van der Ploeg E; Dolsma WV; de Vries EG
    Eur J Cancer; 1993; 29A(5):668-71. PubMed ID: 8471323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes.
    de Graaf H; Willemse PH; de Vries EG; Sleijfer DT; Mulder PO; van der Graaf WT; Smit Sibinga CT; van der Ploeg E; Dolsma WV; Mulder NH
    Eur J Cancer; 1994; 30A(2):150-3. PubMed ID: 8155387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
    Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
    Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN
    J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer.
    Armstrong DK; Fetting JH; Davidson NE; Gordon GB; Huelskamp AM; Abeloff MD
    Breast Cancer Res Treat; 1993 Dec; 28(3):277-84. PubMed ID: 8018956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy in advanced breast carcinoma. Comparison between doxorubicin-cyclophosphamide and cyclophosphamide-methotrexate-5-fluorouracil-vincristine-prednisone.
    Parvinen LM; Numminen S
    Acta Radiol Oncol; 1985; 24(5):391-4. PubMed ID: 3002135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.
    Mundt AJ; Sibley GS; Williams S; Rubin SJ; Heimann R; Halpern H; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):151-60. PubMed ID: 8083108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of induction- and intensification chemotherapy supported with autologous bone marrow reinfusion in patients with disseminated or T4 breast cancer.
    Mulder NH; Dolsma WV; Mulder PO; De Vries EG; Willemse PH; Sleijfer DT; Hospers GA; Van der Graaf WT
    Anticancer Res; 1995; 15(4):1565-8. PubMed ID: 7654046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.
    Spitzer G; Farha P; Valdivieso M; Dicke K; Zander A; Vellekoop L; Murphy WK; Dhingra HM; Umsawasdi T; Chiuten D
    J Clin Oncol; 1986 Jan; 4(1):4-13. PubMed ID: 3510281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study.
    Humblet Y; Symann M; Bosly A; Delaunois L; Francis C; Machiels J; Beauduin M; Doyen C; Weynants P; Longueville J
    J Clin Oncol; 1987 Dec; 5(12):1864-73. PubMed ID: 2824708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
    Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
    Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tandem autotransplantation for the treatment of metastatic breast cancer.
    Broun ER; Sridhara R; Sledge GW; Loesch D; Kneebone PH; Hanna M; Hromas R; Cornetta K; Einhorn LH
    J Clin Oncol; 1995 Aug; 13(8):2050-5. PubMed ID: 7636548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
    Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
    Rischin D; Bishop JF; Olver IN; Laidlaw CR; Zimet A; Jeal P; Dipell JF
    Am J Clin Oncol; 1992 Oct; 15(5):392-4. PubMed ID: 1524039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.
    Koh EH; Buzdar AU; Ames FC; Singletary SE; McNeese MD; Frye D; Holmes FA; Fraschini G; Hug V; Theriault RL
    Cancer Chemother Pharmacol; 1990; 27(2):94-100. PubMed ID: 2249339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
    Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
    Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial.
    Vogel CL; Raney M; Carpenter J
    Cancer Treat Rep; 1987 Dec; 71(12):1271-3. PubMed ID: 3690536
    [No Abstract]   [Full Text] [Related]  

  • 20. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
    Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
    Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.